Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)

ClinicalTrials.gov ID: NCT02019979

Public ClinicalTrials.gov record NCT02019979. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 17, 2026, 7:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Metformin With a Carbohydrate Restricted Diet In Combination With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) - METRO Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Metformin is thought to activate AMP-activated protein kinase (AMPK), a major sensor of cellular energy levels and a key enzyme limiting cellular growth during times of cellular stress. Once activated, this enzyme restricts anabolic processes such as protein, cholesterol and fatty acid synthesis and inhibits mTOR, a protein kinase responsible for unregulated growth. MTOR is upregulated in a variety of tumors, including NSCLC providing rationale to take advantage of this pathway with metformin.

Study identification

NCT ID: NCT02019979
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Beth Israel Medical Center; Other
Enrollment: 14 participants

Conditions and interventions

Conditions

Interventions

metformin Drug
carbohydrate restricted diet Behavioral

Drug · Behavioral

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2013
Primary completion: Nov 30, 2016
Completion: Nov 30, 2016
Last update posted: May 3, 2018

2013 – 2016

United States locations

U.S. sites: 4
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Beth Israel Medical Center	New York	New York	10003	—
Beth Israel Comprehensive Cancer Center	New York	New York	10011	—
St.Luke's-Roosevelt Hospital Center	New York	New York	10019	—
Mount Sinai Ichan School of Medicine	New York	New York	10029	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02019979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 3, 2018 · Synced Sep 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02019979 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →